Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · IEX Real-Time Price · USD
110.31
-0.44 (-0.40%)
At close: May 1, 2024, 4:00 PM
107.00
-3.31 (-3.00%)
After-hours: May 1, 2024, 7:55 PM EDT
Jazz Pharmaceuticals Revenue
In the year 2023, Jazz Pharmaceuticals had annual revenue of $3.83B with 4.78% growth. Revenue in the quarter ending December 31, 2023 was $1.01B with 4.10% year-over-year growth.
Revenue (ttm)
$3.83B
Revenue Growth
+4.78%
P/S Ratio
1.79
Revenue / Employee
$1,369,359
Employees
2,800
Market Cap
6.88B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
Dec 31, 2020 | 2.36B | 201.81M | 9.34% |
Dec 31, 2019 | 2.16B | 270.84M | 14.32% |
Dec 31, 2018 | 1.89B | 272.23M | 16.82% |
Dec 31, 2017 | 1.62B | 130.72M | 8.79% |
Dec 31, 2016 | 1.49B | 163.17M | 12.32% |
Dec 31, 2015 | 1.32B | 151.93M | 12.95% |
Dec 31, 2014 | 1.17B | 300.45M | 34.44% |
Dec 31, 2013 | 872.42M | 286.44M | 48.88% |
Dec 31, 2012 | 585.98M | 313.70M | 115.21% |
Dec 31, 2011 | 272.28M | 98.50M | 56.68% |
Dec 31, 2010 | 173.78M | 45.33M | 35.29% |
Dec 31, 2009 | 128.45M | 60.94M | 90.26% |
Dec 31, 2008 | 67.51M | 2.21M | 3.39% |
Dec 31, 2007 | 65.30M | 20.45M | 45.58% |
Dec 31, 2006 | 44.86M | 23.41M | 109.20% |
Dec 31, 2005 | 21.44M | - | - |
Dec 31, 2004 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elanco Animal Health | 4.42B |
The Ensign Group | 3.73B |
Acadia Healthcare Company | 2.93B |
Masimo | 2.05B |
Exelixis | 1.83B |
Globus Medical | 1.57B |
HealthEquity | 999.59M |
Inspire Medical Systems | 624.80M |
JAZZ News
- 13 hours ago - Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference - PRNewsWire
- 13 hours ago - Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance - PRNewsWire
- 7 days ago - Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024 - PRNewsWire
- 14 days ago - Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 - PRNewsWire
- 21 days ago - Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer - PRNewsWire
- 7 weeks ago - Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 - PRNewsWire
- 2 months ago - Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance - PRNewsWire